BNP (1-32), human|114471-18-0|安捷凯

Background

Basic natriuretic peptide (BNP), now known as B-type natriuretic peptide (also BNP) or GC-B, is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes). The release of BNP is modulated by calcium ions¹. BNP is named as such because it was originally identified in extracts of porcine brain, although in humans it is produced mainly in the cardiac ventricles. The physiologic actions of BNP are similar to ANP and include decrease in systemic vascular resistance and central venous pressure as well as an increase in natriuresis. Thus, the net effect of BNP and ANP is a decrease in blood volume which lowers systemic blood pressure and afterload, yielding an increase in cardiac output, partly due to a higher ejection fraction. The main clinical utility of either BNP or NT-BNP is that a normal level rules out acute heart failure in the emergency setting². Recombinant BNP, Nesiritide is used to treat decompensated heart failure³.

参考文献:
1. Ziskoven D, Forssmann WG, Holthausen U, Menz G, Addicks K, Rippegater G: Calcium Calmodulinantagonists Influences the release of Cardiodilatin/ANP from Atrial Cardiocytes. Handbook Endocrinology of the Heart, edited by Kaufmann W, Wambach G, 01/1989; Springer Verlag Berlin Heidelberg New York;
2. Maisel A, Krishnaswamy P, Nowak R, McCord J, Hollander J, Duc P, Omland T, Storrow A, Abraham W, Wu A, Clopton P, Steg P, Westheim A, Knudsen C, Perez A, Kazanegra R, Herrmann H, McCullough P (2002). "Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure". N Engl J Med 347 (3): 161–7.
3. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. TheNew Englandjournal of medicine 2011;365:32-43.

Protocol

Cell experiment: [1]

Cell lines

Normal adult canine ventricular fibroblasts

Preparation method

The solubility of this peptide in sterile water is >10 mM. Stock solution should be splited and stored at -80°C for several months.

Reaction Conditions

1 μM, 5 min

Applications

BNP (1 μM) significantly increased the intracellular cGMP, whereas lower concentrations did not alter the cGMP. At this concentration, BNP elevated cGMP levels with a maximal effect at 5 minutes. BNP (1 μM) significantly inhibited the [3H]proline incorporation into the cells by 29%.

Animal experiment: [2]

Animal models

Adult Japanese white rabbits

Dosage form

Injected through the sclera into the vitreous cavity, 100 μM, 4 hours

Applications

At 100 μM, BNP treatment induced a significant decrease in IOP compared with vehicle-treated eyes. In particular, there were statistically significant differences at 4 and 6 hours. In addition, BNP treatment at 10 μM caused a significant decrease in IOP compared to the vehicle-treated eyes, but only at 6 hours after the injection.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

参考文献:

[1] Tsuruda T, Boerrigter G, Huntley B K, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circulation research, 2002, 91(12): 1127-1134.

[2] Takashima Y, Taniguchi T, Yoshida M, et al. Ocular hypotensive mechanism of intravitreally injected brain natriuretic peptide in rabbit. Investigative ophthalmology & visual science, 1996, 37(13): 2671-2677.

安捷凯在线客服

扫一扫加微信

信号通路

生命科学

有机化学

无机化学

材料科学

BNP (1-32), human

BNP (1-32), human详情

Background

Protocol

安捷凯在线客服